ArticleThe American journal of pathology2012
Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array.
Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Trial
- Proteomic aging clocks in epidemiological studies: advances, applications and prospects.Nature aging · 2026Review
- Multi-Omics Signatures of Organ Clocks in Biological Aging and Disease: A Conceptual Framework for Organ-Specific Aging Clocks.Aging cell · 2026Review
- Integrated Structural and Glycoproteomic Profiling Reveals Protein Conformational Remodeling and Biomarkers Across Alzheimer's Disease Progression.ACS central science · 2026Article
- Precision geronutrition: personalized nutritional strategies to extend healthy lifespan.BMB reports · 2026Review
- Unveiling proteomic and peptide-level modifications in cerebrospinal fluid and plasma in normal cognitive aging.Communications medicine · 2025Article
- The diagnostic potential of proteomics and machine learning in Lyme neuroborreliosis.Nature communications · 2025Article
- Cerebrospinal fluid proteomic signatures in cognitively normal individuals identify distinct clusters linked to neurodegeneration.Nature aging · 2025Article
- Proteomic Signatures of Epigenetic Age in African Green Monkey Cerebrospinal Fluid and Plasma.Aging cell · 2025Article
- Astrocytes in aging.Neuron · 2025Review
- From bench to bedside: translational insights into aging research.Frontiers in aging · 2025Review
- Review
- Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome.Journal of proteome research · 2024Review
- Senescence- and Immunity-Related Changes in the Central Nervous System: A Comprehensive Review.Aging and disease · 2024Review
- CSF Proteomics in Patients With Progressive Supranuclear Palsy.Neurology · 2024Article
- Plasma and CSF biomarkers of aging and cognitive decline in Caribbean vervets.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Plasma proteomic signature of human longevity.Aging cell · 2024Article
- The choroid plexus maintains ventricle volume and adult subventricular zone neuroblast pool, which facilitates post-stroke neurogenesis.bioRxiv : the preprint server for biology · 2024Article
- Increase in activin A may counteract decline in synaptic plasticity with age.Frontiers in aging neuroscience · 2024Article
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
An important precondition for the successful development of diagnostic assays of cerebrospinal fluid (CSF) biomarkers of age-related neurodegenerative diseases is an understanding of the dynamic nature of the CSF proteome during the normal aging process. In this study, a novel proteomic technology was used to quantify hundreds of proteins simultaneously in the CSF from 90 cognitively normal adults 21 to 85 years of age. SomaLogic's highly multiplexed proteomic platform can measure more than 800 proteins simultaneously from small volumes of biological fluids using novel slow off-rate modified aptamer (SOMAmer) protein affinity reagents with sensitivity, specificity, and dynamic ranges that meet or exceed those of enzyme-linked immunosorbent assays. In the first application of this technology to CSF, we detected 248 proteins that possessed signals greater than twofold over background. Several novel correlations between detected protein concentrations and age were discovered that indicate that both inflammation and response to injury in the central nervous system may increase with age. Applying this powerful proteomic approach to CSF provides potential new insight into the aging of the human central nervous system that may have utility in discovering new disease-related changes in the CSF proteome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.